menu
    • menu

    Company profile for Frequency Therapeutics

    NEW Drugs in Dev: 2
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our initial therapeutic focus is for sensorineural hearing loss (SNHL), which is the most prevalent type of hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells in the cochlea within the ear. FX-322, our lead product candidate...
    We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our initial therapeutic focus is for sensorineural hearing loss (SNHL), which is the most prevalent type of hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells in the cochlea within the ear. FX-322, our lead product candidate, is intended to regenerate hair cells through the activation of progenitor cells already present in the cochlea. We are exploring ways in which our PCA platform may be beneficial in the treatment of multiple sclerosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Frequency TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    19 Presidential Way Woburn, MA 02801
    Telephone
    Telephone
    781-315-4600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.frequencytx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/frequency-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/frequencytx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Progentos emerges with $65M for multiple sclerosis trials with IP from Frequency
    Progentos emerges with $65M for multiple sclerosis trials with IP from Frequency

    20 May 2024

    // ENDPTS

    https://endpts.com/progentos-emerges-with-65m-for-multiple-sclerosis-trials-with-ip-from-frequency/

    ENDPTS
    20 May 2024
    Share Share
    Korro Bio and Frequency Therapeutics Announce Closing of Merger
    Korro Bio and Frequency Therapeutics Announce Closing of Merger

    03 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/03/2773416/0/en/UPDATE-Korro-Bio-and-Frequency-Therapeutics-Announce-Closing-of-Merger-and-Private-Placement-of-117-Million.html

    GLOBENEWSWIRE
    03 Nov 2023
    Share Share
    Frequency Therapeutics Provides Second Quarter 2023 Financial Results
    Frequency Therapeutics Provides Second Quarter 2023 Financial Results

    10 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230810506865/en

    BUSINESSWIRE
    10 Aug 2023
    Share Share
    Korro Bio and Frequency Therapeutics Announce Merger Agreement
    Korro Bio and Frequency Therapeutics Announce Merger Agreement

    14 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230714609713/en

    BUSINESSWIRE
    14 Jul 2023
    Share Share
    Frequency Provides Fourth Quarter and Full Year 2022 Financial Results
    Frequency Provides Fourth Quarter and Full Year 2022 Financial Results

    10 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230310005054/en

    BUSINESSWIRE
    10 Mar 2023
    Share Share
    Frequency Therapeutics to Participate at Upcoming March Investor Conferences
    Frequency Therapeutics to Participate at Upcoming March Investor Conferences

    27 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230227005295/en

    BUSINESSWIRE
    27 Feb 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search